Why Hyperbaric Oxygen Chambers?
Hyperbaric oxygen therapy (HBOT) has migrated from clinical wound-healing centers into the home wellness market. The current consumer market splits sharply by chamber type: soft-shell (mild HBOT, typically 1.3 ATA) — OxyHealth, Summit-to-Sea, Macy-Pan — and hard-shell (high-pressure, 1.5+ ATA) — OxyHelp, OxyRevo, NewTowne. The pressure difference matters: most published HBOT clinical evidence is at 2.0–2.5 ATA, well above what any soft-shell can deliver. Consumer marketing routinely conflates the two, which sets buyers up for disappointment.
What We Compare
Every chamber in our comparison is evaluated on:
- Maximum operating pressure (ATA) — the single most important spec. Soft-shells cap at 1.3–1.4 ATA; hard-shells reach 1.5–3.0 ATA. Published clinical evidence base differs by ATA range.
- FDA clearance status — OxyHealth’s 510(k) (K041007) and a handful of competitors hold device clearances; many imported chambers do not. We name K-numbers where they exist.
- Build type — soft-shell collapsible vs hard-shell rigid. Affects portability, durability, leak risk, and resale value.
- Oxygen-delivery method — concentrator (medical-grade 90%+ O₂) vs ambient air. Many soft-shells include only ambient air at low pressure, which is not equivalent to “hyperbaric oxygen therapy” by the published definition.
- 3-year cost of ownership — chamber + concentrator + replacement masks + electricity. Hard-shells often need a separate medical-grade O₂ concentrator.
Key Findings (2026)
-
OxyHealth dominates US consumer HBOT by volume. 18,000+ units distributed; used in 65% of US hyperbaric clinics; FDA-cleared (K041007). The trade-off is pressure: all OxyHealth soft-shells cap at 1.3 ATA. If you need 1.5+ ATA for the published clinical-evidence range, you need a hard-shell.
-
“Mild HBOT” at 1.3 ATA has weaker published evidence than 2.0+ ATA HBOT. This is the editorial gap in most HBOT marketing. Wound-healing, traumatic-brain-injury, and post-stroke clinical literature is largely at clinical pressure. Consumer 1.3 ATA evidence exists (some neurodegenerative-disease studies) but is methodologically thinner.
-
Imported hard-shell chambers (OxyRevo, Macy-Pan, OxyHelp) often lack FDA clearance. Higher-pressure capability (1.5–3.0 ATA) but variable regulatory status in the US. Buyers should confirm 510(k) clearance status before purchase, especially if planning to file an HSA/FSA reimbursement.
-
A chamber without an oxygen concentrator is not “hyperbaric oxygen.” Soft-shell sales bundles vary — some include a concentrator, some don’t. Ambient air at 1.3 ATA still slightly elevates dissolved O₂, but the published efficacy literature is for high-FiO₂ delivery.
-
3-year TCO is dominated by the concentrator and electricity. A medical-grade O₂ concentrator runs $1,500–$3,000 and consumes 200–400W during sessions. We model these into per-cluster TCO comparisons.
Who Should Read This
- Athletes and biohackers researching home HBOT for recovery
- Buyers comparing soft-shell (OxyHealth, Summit-to-Sea) vs hard-shell (OxyHelp, NewTowne)
- Anyone confused about whether 1.3 ATA “mild HBOT” matches the clinical literature they’ve read
- HSA/FSA buyers needing to confirm a chamber holds FDA clearance for reimbursement eligibility